Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Imfinzi combination improves survival in NSCLC patients

tumour DNA
AstraZeneca’s Imfinzi is a human monoclonal antibody being developed to treat various cancer types. Credit: © AstraZeneca.